We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




After First Approval of a Rapid Molecular Test, Expect More

By LabMedica International staff writers
Posted on 15 Feb 2015
According to Kalorama Information (New York, NY, USA), the first CLIA-waiver approval for broad use of a rapid molecular diagnostic test for influenza, from Alere (Waltham, MA, USA), demonstrates the potential for the molecular point-of-care (POC) sector predicted in Kalorama’s 2014 report. More...


Alere recently announced that the US Food and Drug Administration (FDA) granted the Clinical Laboratory Improvement Amendments (CLIA) waiver for its Alere i Influenza A & B test, allowing for broad use by healthcare providers ranging from hospitals to physician offices and other healthcare settings. It is currently the only clinical molecular test available to detect and differentiate influenza A and B virus in less than 15 minutes.

Kalorama predicted a trend of such decentralized testing approaches in its report “The Market and Potential for Molecular Point of Care Diagnostics.” “Kalorama had indicated last year that POC MDx technologies would hit market near-term, and now this has been realized,” said Bruce Carlson, publisher of Kalorama Information, “There are dozens of other companies that are also working on molecular POC tests, so I’d expect to see more approvals and a competitive marketplace.”

The Alere i test was cleared by the FDA in June 2014 and made available in September 2014 for health facilities licensed to conduct tests of moderate complexity under the CLIA program. Alere said that unlike PCR testing, their proprietary isothermal nucleic acid amplification technology (iNAT) does not require lengthy and complex thermo cycling or even DNA purification, and can therefore deliver PCR-caliber results faster. Clinical performance of Alere i Influenza A & B was established in a multicenter study conducted in the US, in which 630 nasal swab specimens were evaluated with Alere i and compared to an FDA-cleared Real-Time PCR (RT-PCR) assay. Additional disease tests on the Alere i platform are currently in development.

“Now that the first molecular POC has been CLIA-waived, it’s a question of whose test will be next,” said Mr. Carlson, “There are market opportunities in HIV, warfarin sensitivity, sepsis, and other areas where actionable results matter.” Kalorama’s report details these areas and the companies that have products in development. It also provides insight into the potential market for these products, and discusses important platforms and the status of products, reviews deals made, and profiles relevant companies.

Related Links:

Kalorama Information
Report: Market and Potential for Molecular Point of Care Diagnostics 
Alere



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.